Comparative Evaluation of the Efficacy of the Bimatoprost 0.03%, Brimonidine 0.2%, Brinzolamide 1%, Dorzolamide 2%, and Travoprost 0.004%/Timolol 0.5%-Fixed Combinations in Patients Affected by Open-Angle Glaucoma

Abstract

Purpose: This is a retrospective, comparative, head-to-head, not commissioned study about the efficacy of bimatoprost 0.03%, brimonidine 0.2%, brinzolamide 1%, dorzolamide 2%, and travoprost 0.004%/timolol 0.5%-fixed combinations in patients affected by naΐve open-angle glaucoma and IOP > 25 mmHg. Patients and Methods: Files from 70 patients (35 M, 35 F, mean age 69.52 y, S.D. 11.56, range: 37-87 y) in our Glaucoma Service were retrospectively analyzed as long as 12 months. Every subgroup, including 14 age-and sex-matched patients, was allocated to 1 of the 5 groups of the fixed combinations monotherapy. Data recorded after 3 months follow-up were statistically analyzed by descriptive and ANOVA statistics as percentage of IOP reduction from baseline. Results: All the fixed combinations were effective in lowering IOP. The mean percentage reduction was: brimonidine/timolol 43.57%, dorzolamide/timolol 37.67%, bimatoprost/timolol 35.60%, travoprost/timolol 33.25% and brinzolamide/timolol 23.0%. The brimonidine/timolol fixed combination showed to be statistically significant more effective only than brinzolamide/timolol fixed combination (p = 0.001). Setting the α error to 5%, the power of the study is 26%, phi: 0.842. Discussion: In all this cohort of patients the target IOP was successfully achieved. All the fixed combinations used in this study had a very good profile of efficacy. Brimonidine, dorzolamide, bimatoprost and travoprost/timolol fixed combinations statistically significantly reduced the percentage of IOP from baseline (p = 0.001) more than brinzolamide/timolol fixed combination.

A comparative study of the clinical efficacy and safety of timolol 0.5% and travoprost 0.004% eye drops in primary open angle glaucoma

“…Our observations regarding age distribution are consistent with the other studies done by Mehani R et al, Khan F et al and Babić N et al 7,9,10 However in a study by Jeffrey A et al mean age of study subjects were 63.4±12.3 and 62.7±12.4 and a study done by Giuffre I revealed the mean age of subjects as 69.52 years. 11,12 In our study male predominance was found which was in accordance with other observations seen in studies done by Mehani R et al, Khan F et al and Parrish RK et al 7,9,13 Raised intra ocular pressure is a major risk factor for development POAG, several randomized controlled trials have determined that reducing IOP can reduce rate of glaucomatous nerve or field damage. 5,6 In our study, in timolol group there was significant reduction in IOP from baseline to week 4.…”

The Relationship between Central Macular Thickness and Metabolic Parameters Changes in Patients with Non-Proliferative Diabetic Retinopathy

“…Presently, IOP reduction is the only evidence-based therapy available for glaucoma management. [3] The first-line of topical anti-glaucoma therapy includes prostaglandin analogs and β-blockers. Other options available are carbonic anhydrase inhibitors (e.g.…”